

Wide application of minimally processed saliva on multiple RT-qPCR kits for SARS-CoV-2 detection in Indonesia

1 Authors

2 Caroline Mahendra^{1†}, Maria Mardalena Martini Kaisar^{2†}, Suraj Rajan Vasandani^{1†}, Sem Samuel
3 Surja², Enty Tjoa², Febie Chriestya^{2,4}, Kathleen Irena Junusmin¹, Tria Asri Widowati², Astrid
4 Irwanto^{1,3}, Soegianto Ali^{2*}

5

6 Affiliations

7 ¹Nalagenetics Pte Ltd, Singapore, Singapore

8 ²School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta,
9 Indonesia

10 ³Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

11 ⁴Rumah Sakit Pendidikan & Pusat Penelitian Atma Jaya, Jakarta, Indonesia

12

13 †These authors have contributed equally to this work and share first authorship

14 * Correspondence:

15 Soegianto Ali, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia,
16 Pluit Raya No. 2, Jakarta 14440, Indonesia.
17 soegianto.ali@atmajaya.ac.id

18

19 **Keywords: saliva, SARS-CoV-2, real-time PCR, direct-PCR, stability, RNA-extraction-free,**
20 **large capacity, COVID-19. (Min.5-Max. 8)**

21

22 **Abstract** (172 words)

23 Saliva as a sample matrix has been an attractive alternative for the detection of SARS-CoV-2. However,
24 due to potential variability in collection and processing steps, evaluating a proposed workflow amongst
25 the local population is recommended. Here, we aim to validate the collection and treatment of human
26 saliva as a direct specimen for RT-qPCR-based detection of SARS-CoV-2 in Indonesia. We
27 demonstrated that SARS-CoV-2 target genes were detected in saliva specimens and remained stable
28 for five days refrigerated or room temperature storage. The method of processing saliva specimens
29 described in this report bypasses the need for an RNA-extraction process, thereby reducing the cost,
30 time, and manpower required for processing samples. The developed method was tested across nine
31 commercial kits, including the benchmark, to demonstrate its wide applicability on multiple existing
32 workflows. Our developed method achieved 86% overall agreement rate compared to paired
33 nasopharyngeal and oropharyngeal swab specimens (NPOP). With the assistance of a saliva sampling
34 device, the collection was found to be more convenient for individuals and improved the overall
35 agreement rate to 97%.

36

37 Words count: 4403 words.

38 Number of figures: 6 figures in 4 groups.

39 Number of tables: 4 tables.

40 1. Introduction

41 COVID-19 case was first reported to the World Health Organization (WHO) on December 31, 2019,
42 and was declared a pandemic on March 11, 2020 (Timeline of WHO's response to COVID-19).
43 COVID-19 is caused by SARS-CoV-2 viral infection, an enveloped virus with single-stranded
44 positive-strand genomic RNA (Brian and Baric, 2005). One of the modalities used to diagnose COVID-
45 19 is nucleic acid amplification test (NAAT), including Reverse Transcription quantitative Polymerase
46 Chain Reaction (RT-qPCR), which commonly targets the envelope (E), nucleocapsid (N), RNA-
47 dependent RNA polymerase (RdRP), and spike (S) genes (World Health Organization, 2020).
48 Specimens that could be used for NAAT include those obtained from the upper and lower respiratory
49 tracts and gastrointestinal tracts (Wang et al., 2020). Specimens commonly collected from the upper
50 respiratory tracts are nasopharyngeal and oropharyngeal (NPOP) swabs, and those obtained from the
51 lower respiratory tract include bronchoalveolar lavage. The rate of detecting positive infection from
52 bronchoalveolar lavage is superior to that of NPOP swabs; however, it is commonly obtained from
53 inpatients with severe illness or those undergoing mechanical ventilation (Wang et al., 2020). The stool
54 has also been used as a specimen for NAAT methods for SARS-CoV-2 detection, including among
55 children (Zhang et al., 2020).

56 Collecting NPOP specimens require trained healthcare personnel and could induce aerosolization that
57 increases the risk of infection to healthcare personnel. Adequate Personal Protective Equipment (PPE)
58 is needed, and specimen collection can only be done in designated sites to reduce the risk of
59 transmission during the procedure. Indonesia is a very vast country with varying levels of access to
60 collection sites at medical facilities. Patients with suspected infections located far from urban facilities
61 may need to travel on public transport for a period of time to arrive at medical centers for NPOP
62 collection (COVID-19 developments in Indonesia). Such situations could increase the risk of disease
63 spread from the individuals' exposure to the mass population during his/her travel.

64 Other studies have shown that saliva can serve as an alternative specimen for NAAT-based SARS-
65 CoV-2 detection (Hung et al., 2020; Wyllie et al., 2020). Its non-invasive nature reduces the level of
66 discomfort experienced when sampling, minimizes production of aerosols and does not require a
67 trained healthcare provider, which could allow for flexibility of sampling at various collection sites,
68 including at-home. Although there is a reduction in sensitivity to detecting SARS-CoV-2 from saliva
69 specimens, its specificity remained at par with NPOP specimens, suggesting that saliva is still a reliable
70 specimen (Griesemer et al., 2020; Landry et al., 2020; Xu et al., 2020).

71 The standard protocol for detecting SARS-CoV-2 using the RT-qPCR method from NPOP swabs
72 requires various consumables. The NPOP swab should be immersed in Viral Transport Medium (VTM)
73 for transportation from the collection site to the laboratory and maintained in cold condition. In the
74 laboratory, the VTM containing NPOP specimens are extracted to isolate viral RNA. This step
75 generally utilizes a commercial RNA extraction kit, which could take up to 1 – 1.5 hours to complete.
76 Purified viral RNA then will be used as a template for RT-qPCR amplification which takes 2 – 3 hours
77 from reaction set up to complete. The whole procedure could take 3 – 4.5 hours from sample collection
78 to result reporting.

79 Previous reports have demonstrated comparable results of performing RT-qPCR directly from NPOP
80 without the RNA extraction step (Alcoba-Florez et al., 2020; Smyrlaki et al., 2020). Direct PCR omits
81 the need for RNA extraction kits and reduces the turnover time by 1 – 1.5 hours. Currently, in
82 Indonesia, most RNA extraction kits are imported, and particularly during this pandemic, it can be
83 scarce.

84 Considering the above-mentioned possibilities, we tested and validated the detection of SARS-CoV-2
85 by RT-qPCR from minimally processed saliva specimens. The validated method would be more

86 convenient for patients, safer for healthcare providers and reduce the time and cost of the current RT-
87 qPCR test to detect COVID-19 infection.

88

89 **2 Materials and Methods**

90 **2.1 Ethical Clearance**

91 The collection of clinical specimens, NPOP swabs, and saliva specimens were approved by the
92 Institutional Review Board of the School of Medicine and Health Sciences, Atma Jaya Catholic
93 University of Indonesia (No:16/11/KEP-FKIKUAJ/2020).

94

95 **2.2 Study Recruitment**

96 Recruitment for study participants was done in collaboration with multiple SARS-CoV-2 testing sites.
97 Participants were verbally informed about the study and the procedures involved. Written informed
98 consent was obtained from all participants prior to specimen collection. Inclusion criteria for this study
99 were patients who tested positive up to 14-days before specimen collection or were in close contact
100 with a known positive patient. Exclusion criteria were patients who were critically ill, unconscious,
101 and/or intubated.

102 **2.3 Specimen Collection**

103 Collection of NPOP swabs and saliva specimens were performed for every patient and within one hour
104 of each other. NPOP swabs were collected by a trained medical professional by inserting separate
105 swabs into the participants' nasopharyngeal (NP) and oropharyngeal (OP) cavity and immersed into a
106 single tube containing VTM. Prior to saliva specimen collection, patients were required to satisfy a 30-
107 minute fasting period during which they were prohibited from eating, drinking, smoking, tooth
108 brushing, using mouthwash, and other activities that involved the oral cavity. Approximately 2-5 mL
109 of unstimulated saliva was collected into a 50 mL tube without the addition of buffers or any other
110 stabilizing medium. Specimens were then kept on ice during transport and processed in an enhanced
111 Biosafety Laboratory Level 2 facility at the School of Medicine and Health Sciences, Atma Jaya
112 Catholic University of Indonesia.

113 **2.4 Viral RNA Extraction**

114 Viral RNA was extracted with QIAamp Viral RNA Mini kit (Catalog # 52906, Qiagen, Hilden
115 Germany) following instructions provided by the manufacturer. In brief, 140 μ L of VTM containing
116 NPOP swabs or saliva specimens was mixed with lysis buffer, bound to silica membrane present in the
117 spin column, washed twice, and eluted (60 μ L) as pure RNA.

118 **2.5 Viral Nucleic Acid Detection with RT-qPCR**

119 Da An Gene's Detection Kit for 2019 Novel Coronavirus (2019-nCoV) RNA (PCR-Fluorescence
120 Probing) (Catalog # DA-930) was used as the reference nucleic acid detection kit in this study. The
121 RT-qPCR master mix was prepared following the manufacturer's recommended instruction - 17 μ L of
122 PCR reaction solution A and 3 μ L of PCR reaction solution B for each reaction. The template (5 μ L)
123 used was either extracted viral RNA (section 2.4), or RNA-extraction-free treated saliva specimens
124 (section 2.9). Upon template addition, strip tubes were briefly spun down to ensure that all liquid is

125 positioned at the bottom of the tube. Thermocycling conditions were as follows: 15 minutes at 50°C,
126 15 minutes at 95°C, and 45 cycles of 15 seconds at 94°C and 45 seconds at 55°C. The amplification,
127 detection, and analysis were performed using the CFX96 Touch Real-Time PCR detection system (Bio-
128 Rad laboratories). Negative and positive controls were included in each RT-qPCR run. Cycle threshold
129 (Ct) values were analyzed using CFX Maestro software (Bio-Rad laboratories). The Ct-value results
130 represent the amplification cycle in which the fluorescence signal level exceeds the background
131 fluorescence, reflecting the presence of SARS-CoV-2 RNA in the specimen tested. Specimens were
132 interpreted as positive if the cycle threshold (Ct) values for N-gene and ORF1ab were less than 40, and
133 the curve displayed apparent amplification in the typical "S" shaped form. Specimens with no
134 amplification (N/A) or Ct values > 40 for both genes but had internal control amplified were interpreted
135 as negative. Specimens that only had amplification in one of the target genes, N-gene or ORF1ab but
136 not both, or no amplification at all across all the channels, were interpreted as invalid in this study.

137 **2.6 Viability of Saliva as a Sample Matrix**

138 Paired NPOP and saliva specimens were collected and used to show the viability of saliva as a sample
139 matrix to detect SARS-CoV-2 RNA (n=116). Viral RNA from both specimens was extracted with the
140 QIAamp Viral RNA Mini kit (section 2.4). Detection of viral RNA from both specimen types was done
141 on our reference kit (section 2.5).

142 **2.7 Optimization of RNA-extraction free treatment for saliva specimens**

143 Optimization of RNA-extraction-free treatment of saliva specimens was performed on six previously
144 diagnosed specimens, consisting of positives (n=3) and negatives (n=3). Viral RNA was extracted from
145 NPOP and saliva specimens (section 2.4) before subjected to RT-qPCR to detect SARS-CoV-2 (section
146 2.5) (**Figure 1A**, Treatments 1 and 2). The remaining saliva specimens were vortexed, aliquoted as
147 100µL into six 1.5mL microtubes, and subjected to the different RNA-extraction-free treatments
148 (**Figure 1A**, Treatments 3 to 8) before added as templates into the RT-qPCR reaction for viral RNA
149 detection (**Supplementary 1**)(section 2.5).

150 The effectiveness of RNA-extraction-free treatment of saliva specimens was evaluated by comparing
151 Ct values on positive saliva specimens (n=55) that were subjected to RNA extraction Treatment 2 and
152 optimized RNA-extraction-free Treatment 6 (**Figure 1A**, **Supplementary 1**)

153 **2.8 Saliva Specimen Stability for RNA-Extraction-free Treatment**

154 Saliva specimens with Ct values ranging from 14.24 to 32.85 for N-gene and 18.15 to 35.18 for
155 ORF1ab were monitored for specimen stability (n=14). Collected saliva specimens were aliquoted into
156 100µL in 1.5mL microtubes and stored at room temperature (~25°C) or inside a refrigerator (2-8°C).
157 Specimens stored at room temperature were tested daily for five days, while those stored in the fridge
158 were tested on days three through five. A tube from each storage condition was retrieved for each time
159 point, and RNA-extraction-free treatment of saliva specimens (section 2.9) was carried out before
160 subjecting specimens to RT-qPCR (section 2.5).

161 **2.9 Validating RNA-extraction-free Treatment of Saliva Specimens**

162 Paired NPOP and saliva specimens were collected and used to assess the performance of our RNA-
163 extraction-free treatment of saliva specimens (Treatment 6; **Figure 1A**, **Supplementary 1**) against
164 extracted viral RNA from NPOP specimens (n=125). Collected specimens arriving in the laboratory
165 were stored in a refrigerator at approximately 2-8°C and processed within 5 days of the collection date.
166 Viral RNA from NPOP swabs and treated saliva were then used as RT-qPCR templates (section 2.5).

167 **2.10 Compatibility with Other SARS-CoV-2 RT-qPCR Detection Kits**

168 We assess the compatibility of this method with eight more commercial kits other than the reference,
169 following instructions provided by each manufacturer. Details of genes targeted, internal control, the
170 limit of detection, the number of cycles, cycle threshold cut-off, and template volume are summarized
171 in **Supplementary 2**. Evaluation of each kit was done on specimens previously characterized by our
172 reference kit (n=10 to 13). The samples selected as a pool to subject to different kits should contain at
173 least two positives. Positive samples selected had target genes detected with Ct range from 17.07 to
174 35.54 for N-gene and 18.48 to 37.14 for ORF1ab.

175 For kits that required internal control to be added into specimens prior to extraction (Fosun and
176 Maccura), the step was modified to add internal control into the RT-qPCR master mix at 0.1x of its
177 recommended volume. The amplification, detection, and analysis were performed using the CFX96
178 Touch Real-Time PCR detection system and CFX Maestro software (Bio-Rad laboratories).

179 **2.11 Implementation of a Saliva Collection Device**

180 Paired NPOP swab and saliva specimens were collected from collaborating sites during the
181 implementation of the saliva collection device, QuickSpit™ (n=306). NPOP swab specimens were
182 collected and underwent RNA extraction following standard procedures performed by the
183 collaborating sites. NPOP results obtained were used as the benchmark for this experiment. Saliva
184 specimens were collected at 0.5-1.0 mL with QuickSpit™ following instructions for use and processed
185 with RNA-extraction-free treatment before being subjected to RT-qPCR (section 2.5).

186 **2.12 Data Management and Statistical Analysis**

187 Collected respondent's information and RT-qPCR data were stored in a Microsoft Excel database with
188 restricted sharing to authors only. Two-by-two contingency matrices were used to compare PCR results
189 from extracted NPOP and test conditions: extracted saliva (section 2.6), treated saliva (section 2.9),
190 and treated saliva collected with QuickSpit (section 2.12). Only specimens that returned positive or
191 negative results on both conditions were included in calculating agreement rates. Results were reported
192 as overall agreement, positive percent agreement (PPA), and negative percent agreement (NPA), each
193 with 95% scores of confidence interval (95% CI) calculated using the following formulas:

$$194 \text{ Overall agreement (\%)} = \frac{\text{positive}_{(\text{NPOP, tested condition})} + \text{negative}_{(\text{NPOP, tested condition})}}{\text{total number of specimens}} \times 100$$

$$195 \text{ PPA (\%)} = \frac{\text{positive}_{(\text{NPOP, tested condition})}}{\text{positive}_{(\text{NPOP, tested condition})} + \text{positive}_{(\text{NPOP})} \text{negative}_{(\text{tested condition})}} \times 100$$

$$196 \text{ NPA (\%)} = \frac{\text{negative}_{(\text{NPOP, tested condition})}}{\text{negative}_{(\text{NPOP, tested condition})} + \text{negative}_{(\text{NPOP})} \text{positive}_{(\text{tested condition})}} \times 100$$

197 Paired two-tailed t-tests were performed to compare the means of Ct value between different saliva
198 specimen treatments (section 2.7) and between the mean difference of the varying saliva storage
199 conditions (section 2.8). The null hypothesis stated there is no difference in means of Ct value across
200 the tested conditions. Differences with a *p-value* < 0.05 were considered to be statistically significant.
201 Statistical analysis and data visualization were performed using GraphPad Prism version 8 (GraphPad
202 Software, La Jolla, CA USA) and Microsoft Excel for Windows.

203 The compatibility of the developed method with different RT-qPCR kits was assessed by comparing
204 results obtained on the evaluated kits to those obtained on the reference kit. Results were reported as
205 the rate of invalid specimens, overall agreement, and estimated sensitivity calculated with the following
206 formulas:

$$207 \text{ Invalid rate (\%)} = \frac{\text{invalid specimens}}{\text{sample size}} \times 100$$

$$208 \text{ Overall agreement (\%)} = \frac{(\text{true positive} + \text{true negative})}{\text{true positive} + \text{false positive} + \text{true negative} + \text{false negative}} \times 100$$

$$209 \text{ Estimated sensitivity (\%)} = \frac{\text{true positive}}{\text{true positive} + \text{false negative}} \times 100$$

210 True positives or negatives were defined as specimens that had concordant results on the evaluated and
211 reference kit. False results were defined as specimens that had discordant results – specimens that were
212 positive on the evaluated kit but negative on reference were interpreted as false positives, while
213 specimens that were negative on the evaluated kit but positive on reference were interpreted as false
214 negatives. The specimens that did not return a result on the evaluated kit were defined as invalid.

215

216 **3 Results**

217 **3.1 Transitioning from NPOP swab to saliva for detection of SARS-CoV-2 by RT-qPCR**

218 We first sought to validate saliva as a specimen suitable for the detection of SARS-CoV-2 by RT-
219 qPCR. A total of 103 samples returned positive or negative results on both specimens out of the
220 collected 116 samples. We found an 89.3% overall agreement between specimens extracted from saliva
221 and NPOP, consisting of 84.5% positive percent agreement (PPA) and 100% negative percent
222 agreement (NPA) (**Table 1, Supplementary 3**). Eleven specimens tested negative on saliva but
223 positive on NPOP. This shows the viability of saliva specimens in detecting SARS-CoV-2.

224 **3.2 Development of an RNA-extraction-free treatment of saliva for detection of SARS-CoV-2**

225 To streamline sample treatment for downstream RT-qPCR application, we explored several treatment
226 methods on saliva specimens. This included saliva undergoing heating, the addition of Proteinase K,
227 and concentrating by centrifugation paired with RNA extracts from NPOP and saliva as templates for
228 RT-qPCR reaction (**Figure 1A, Supplementary 1**). We found all treatment methods on saliva
229 specimens resulted in the same qualitative outcome on positive specimens and comparable Ct values
230 for the two target genes (**Figure 1B**).

231 Given the need for an affordable and scalable yet effective method, we developed a specimen treatment
232 that only involved the heating of saliva (**Figure 1A, Treatment 6**). Paired t-test analysis was done
233 between Ct values obtained from positive specimens extracted from NPOP swabs, Treatment 1, and
234 RNA-extraction-free treatment of saliva specimens, Treatment 6. There was no significant difference
235 in detection of N-gene (*p-value* = 0.102) and ORF1ab (*p-value* = 0.107), demonstrating effectiveness
236 of SARS-CoV-2 detection from heat-treated saliva specimen as compared to RNA extract from NPOP
237 swabs. This method also confirmed qualitative results on negative specimens (**Supplementary 4**).

238 We generated a linear regression from positive saliva specimens to demonstrate the effectiveness of
239 RNA-extraction-free treatment of saliva specimens, Treatment 6, compared to those subjected to RNA
240 extraction, Treatment 2 (n=55). A strong positive correlation in Ct value for N-gene (coefficient = 1.00,

241 $R^2 = 0.929$) and ORF1ab (coefficient = 0.966, $R^2 = 0.837$) was observed demonstrating that the
242 Treatment 6 is effective for detection of viral RNA in saliva (**Figure 2**).

243 **3.3 SARS-CoV-2 in saliva specimens remained stable at 4°C and room temperature (RT)**

244 To determine the storage condition for saliva specimens that maintain effective treatment and detection
245 of SARS-CoV-2, we monitored specimen stability at two temperatures on previously confirmed
246 positive saliva specimens for five days (n=14). Each specimen was then subjected to heat treatment
247 followed by RT-qPCR detection at selected time points during the period of storage. We found that
248 detection of both target genes remained stable for 5 days at both storage conditions for specimens from
249 low to high viral load with initial Ct ranging from 14 to 35 (**Figure 3, Supplementary 5**).

250 On detection of N-gene, we found no significant difference in Ct values upon storage for 5 days at 4°C
251 ($\Delta Ct = 0.52$, p -value = 0.262) and room temperature ($\Delta Ct = 1.00$, p -value = 0.066). There was no
252 significant difference in the detection of N-gene between storing specimens at both temperatures (p -
253 value = 0.341). ORF1ab detection slightly improve upon storing for a period of 5 days, as seen in the
254 decrease in Ct value at 4°C ($\Delta Ct = -0.386$, p -value = 0.295) and room temperature ($\Delta Ct = -0.281$, p -
255 value = 0.559), although there was no significant difference between the two temperatures (p -value =
256 0.671). This shows that SARS-CoV-2 remain stable in saliva specimens for up to five days on both
257 storage conditions.

258 **3.4 RNA-extraction-free treatment of saliva specimens is reliable for detecting SARS-CoV-2**

259 To assess the performance of the developed method, patients were recruited with written informed
260 consent for collection of NPOP swabs and saliva at the same time point by health care workers. A total
261 of 110 samples returned positive or negative results on both specimens out of the collected 125 samples.
262 NPOP specimens were subjected to QIAamp Viral RNA Extraction, while saliva specimens were
263 treated under the RNA-Extraction-free method, and both were applied as a template for subsequent
264 RT-qPCR detection. We found the overall percent agreement between RNA extract from NPOP swabs
265 and treated saliva specimens to be 86.4%, with 79.2% PPA and 100% NPA (**Table 2, Supplementary**
266 **6**). Fifteen specimens tested different results across the two specimen types. This was expected due to
267 variation in specimen types but did not rule out the validity of this method of saliva treatment.

268 **3.5 Heat-treated saliva specimen is versatile with a number of SARS-CoV-2 RT-qPCR kits**

269 To assess the versatility of the developed method for saliva treatment, we subjected the heat-treated
270 saliva specimens (n= 10 to 13) for detection using eight more commercial SARS-CoV-2 RT-qPCR kits
271 (**Supplementary 2**). Results obtained were then compared to the reference kit that this treatment
272 method was developed on, Da An Gene. The parameters of interest to assess compatibility of the
273 treatment with a commercial kit were their performance at generating invalid results and overall
274 agreement to results produced by the reference kit.

275 Most of the kits tested generated invalid rates of under 10%, demonstrating that the treatment did not
276 risk inhibiting reactions of other commercial kits, except for Vazyme which had 40% invalid rates
277 (n=4/10). Two kits obtained results that were in 100% agreement to the reference, Maccura (n=11/11)
278 and Fosun (n=11/11). Ardent (n=10/11) and SD Biosensor (n=11/12) displayed above 90% agreement,
279 followed by Biosewoom at 80% (n=8/10) and Fortitude 70% (n=7/10). 3S and Vazyme had the lowest
280 agreement to the reference, 40% (n=4/10) and 33% (n=2/6) respectively (**Table 3**). Upon closer
281 inspection, the lower overall agreement generated by 3S and Vazyme (n=4/6) were contributed from
282 detection of false positives (3S n=6/10; Vazyme n=4/6; **Supplementary 7**). This could arise due to
283 their limit of detection being lower than the reference kit, resulting in samples of lower viral load

284 detectable by 3S and Vazyme but not by Da An Gene (**Supplementary 2**). Together, our results
285 demonstrated that most kits were compatible with the developed method for treatment of saliva with
286 varying performance, indicating that validation is recommended before implementing the method with
287 any existing workflow.

288 **3.6 Implementation of saliva collection and treatment method for SARS-CoV-2 diagnostics**

289 To better assist with the saliva specimen collection process, we utilized the QuickSpit™ Collection Kit
290 for an easy and safe sampling of human saliva. The study recruitment was continued at multiple
291 collaborating sites using the QuickSpit™ Collection kit. Paired NPOP swabs and saliva were collected
292 and processed to evaluate the percent agreements between extracted RNA from NPOP specimens and
293 RNA-extraction-free treatment of saliva specimens collected with QuickSpit™. A total of 293 samples
294 returned positive or negative results on both specimens out of the collected 306 samples (**Table 4,**
295 **Supplementary 8**). The use of a collection device improved the agreement between treated-saliva and
296 extracted-NPOP methods of SARS-CoV-2 treatment before RT-qPCR detection, where 90% overall
297 agreement was observed with PPA at 85% and NPA at 100%.

298 **4 Discussion**

299 Numerous references have reported the use of human saliva as an attractive specimen for detection of
300 SARS-CoV-2 infection for its practicality in sampling and processing (Ott et al.; Azzi et al., 2020;
301 Iwasaki et al., 2020; Vogels et al., 2020; Watkins et al., 2020; Wyllie et al., 2020; Xu et al., 2020).
302 Utilizing saliva specimens allows for convenient self-collection without the need for a medical
303 professional inserting swabs into a patient's nasopharyngeal and/or oropharyngeal cavity. In this study,
304 we validated the application of human saliva as a candidate specimen for detecting SARS-CoV-2,
305 achieving 90% agreement with the current conventional specimens - NPOP swabs. Although some
306 discordance was observed between NPOP swabs and saliva specimens, this is in conjunction with
307 previous reports that some variation exists between specimen types (Griesemer et al., 2020; Landry et
308 al., 2020; Vogels et al., 2020; Xu et al., 2020). This could arise from individuals bearing the virus only
309 in their nasopharyngeal cavity but not in their oral cavity. NPOP swab collects specimen from both
310 respiratory tract sites into a single VTM-containing tube, whereas saliva specimens only collect from
311 the oral cavity. Further investigation on the viral pathway of infection is needed to understand these
312 cases of discordance between specimen types. Results obtained in this study still confirm that saliva is
313 a viable alternative specimen for SARS-CoV-2 detection.

314 Our developed method could increase the scale of SARS-CoV-2 testing since the treatment requires
315 less manpower and time. Furthermore, minimally processed saliva specimens reduce the cost of testing
316 by two-folds: 1) exempting the cost of trained professionals for specimen collection and the need of
317 VTM and swabs, and 2) removing the need for the RNA extraction process. Saliva specimen collection
318 could be performed at home and sent to the laboratory in a safe box, hence omitting the need for the
319 suspected person to travel to the diagnostic center and, thereby, reduce the chances of transmission that
320 could occur during the journey.

321 The invalid rate for testing saliva was 2% higher than NPOP specimens (invalid specimens in saliva =
322 7.8% (n=116); NPOP = 5.1% (n=564)) (**Supplementary 9**). This could arise from the carryover of
323 interfering substances from the oral cavity during collection, which was observed in some specimens
324 that were colored, viscous, and/or particulate. Such substances are also potential causes of reaction
325 inhibitors, as seen in the increase of invalid rates from 7% (n=116) in extracted saliva to 8.8% (n=125)
326 with treated saliva. The use of a saliva collection device reduced invalid rates on saliva specimens to
327 3.6% (n=306) and improved agreements between treated-saliva and extracted NPOP for viral detection.

328 Overall improvement was seen at an increase of 5% for all agreements from not using a collection
329 device, demonstrating that collecting less volume and using a designated saliva collection device was
330 more effective. The use of a collection device improved the quality of saliva collected that was visually
331 less viscous, less particulate, and uniformly clear-colored, leading to less accumulation of potential
332 inhibitors.

333 It is also important to always consider handling precautions during the collection and processing of
334 saliva via heat treatment alone, as the presence of contaminants may inhibit the RT-qPCR reaction.
335 This includes avoiding powdered gloves during collection, transport, and handling, as they are common
336 PCR inhibitors (Lomas et al., 1992; Broyles et al., 2002). Good laboratory practices recommend the
337 use of nitrile gloves in a molecular laboratory (Viana and Wallis).

338 One of the highlights of our study is that we also monitored the stability of saliva specimens and found
339 it remained stable at cold (2-8°C) and room temperature in the laboratory (~25°C) for up to 5 days. Our
340 finding is concordant with previous studies done by spiking SARS-CoV-2 into saliva specimens
341 (Williams et al., 2021). SARS-CoV-2 may remain stable in saliva despite the presence of RNases in
342 the medium due to its hard outer shell (Goh et al., 2020). This finding is promising for the utilization
343 of saliva specimens in vast countries like Indonesia, where sending specimens from remote areas to
344 diagnostic centers could take days. Nevertheless, we recommend using iceboxes during the
345 transportation of saliva specimens as outside temperature during the day could be hotter than 30°C
346 (WEATHER AND CLIMATE IN INDONESIA | Facts and Details). Once arrived at the laboratory,
347 saliva specimens should also be processed as soon as possible. The sooner the diagnosis is made for
348 the suspected patient; the sooner subsequent measures could be taken, hence limiting the transmission
349 of the disease.

350 This method could also be used for serial screening of workplaces or schools as frequent NPOP
351 swabbing causes discomfort. The 97% overall agreement of this method is superior compared to the
352 antigen swab (Mak et al., 2020; Scohy et al., 2020). The developed method of treatment is versatile for
353 several commercial SARS-CoV-2 RT-qPCR kits available in Indonesia. Although there was no
354 particular association observed between the compatibility of saliva undergoing RNA-extraction-free
355 treatment and kits' characteristics, we demonstrated that this method could be adopted with several
356 commercial kits. This allows the implementation of minimally treated saliva specimens across
357 laboratories utilizing various commercial RT-qPCR kits without disrupting their existing workflows,
358 with prior validation of their compatibility highly recommended.

359 The limitation of this study is that we did not retest the invalid samples for confirmation. Expert
360 guidelines recommend repeating the test process when samples return an invalid result, either with the
361 same workflow or, if available, using an alternate RT-qPCR kit to avoid reporting invalid
362 (Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia, 2020). This
363 process of retesting is highly recommended to be implemented with treated saliva as well. Hence a
364 future study on this would elucidate the cause of discordance between specimen types.

365 In conclusion, we validated the use of human saliva as a viable alternative specimen to detect SARS-
366 CoV-2 via direct RT-qPCR. Saliva can be collected in a tube without additives and remained stable at
367 cold and room temperature for five days of storage. Upon arrival in the laboratory, saliva specimens
368 can be treated against the heat incubation method alone, followed by immediate addition as a template
369 for RT-qPCR reaction (**Figure 4**).

370

371 **5 Competing interest**

372 CM, SV, KIJ, and AI are employees of Nalagenetics Pte Ltd, Singapore, holding the trademark of
373 QuickSpit™. AI has financial holdings in Nalagenetics Pte Ltd, Singapore. CM, MMMK, SV, and SA
374 have filed a patent (Patent application number: S00202103063) on the RNA-Extraction-free treatment
375 of saliva specimens for SARS-CoV-2 diagnosis.

376

377 **6 Author contributions**

378 Contributed to study design: CM, SA, MMMK, SRV. Contributed to patient recruitment: SRV, SSS,
379 MMMK, ET, FC, KIJ. Performed laboratory experiments: SRV, TAW, MMMK. Contributed to patient
380 data management: SA, CM. Data analysis: CM, SRV, MMMK, SA. Manuscript writing: CM, SRV,
381 SA, MMMK. Supervised and conceived the study: CM, SA, AI. All authors have reviewed the
382 manuscript.

383

384 **7 Funding**

385 The study was funded by the internal research grant of Atma Jaya Catholic University of Indonesia
386 and Nalagenetics Pte. Ltd. The study was independently designed.

387

388 **8 Acknowledgments**

389 We would like to thank all the participating healthcare personnel and volunteers of our collaborating
390 sites for contributing to specimen collection: FKIK Atma Jaya, Rumah Sakit Atma Jaya, Rumah
391 Sakit EMC Tangerang, Intibios Lab Mangga Besar, Intibios Lab Pantai Indah Kapuk, and PT
392 Nalagenetik Riset Indonesia. We would also like to acknowledge all patients and respondents who
393 have voluntarily provided their specimen for this study, Sheila Jonnatan for her assistance in the early
394 stage of the laboratory work, COVID-19 Laboratory (AJCUI) for providing the different RT-qPCR
395 kits, and members of PT Nalagenetik Riset Indonesia in assistance for QuickSpit™ design and
396 development. This work was supported by the COVID-19 Laboratory Center of Atma Jaya Catholic
397 University of Indonesia (AJCUI).

398

399 **9 References**


- 400 Alcoba-Florez, J., González-Montelongo, R., Íñigo-Campos, A., de Artola, D. G.-M., Gil-
401 Campesino, H., Team, T. M. T. S., et al. (2020). Fast SARS-CoV-2 detection by RT-qPCR in
402 preheated nasopharyngeal swab samples. *Int. J. Infect. Dis.* 97, 66–68.
403 doi:10.1016/j.ijid.2020.05.099.
- 404 Azzi, L., Carcano, G., Gianfagna, F., Grossi, P., Gasperina, D. D., Genoni, A., et al. (2020). Saliva is
405 a reliable tool to detect SARS-CoV-2. *J. Infect.* 81, e45–e50. doi:10.1016/j.jinf.2020.04.005.
- 406 Brian, D. A., and Baric, R. S. (2005). Coronavirus genome structure and replication. *Curr. Top.*
407 *Microbiol. Immunol.* 287, 1–30. doi:10.1007/3-540-26765-4_1.
- 408 Broyles, J. M., O’Connell, K. P., and Korniewicz, D. M. (2002). PCR-based method for detecting

- 409 viral penetration of medical exam gloves. *J. Clin. Microbiol.* 40, 2725–2728.
410 doi:10.1128/jcm.40.8.2725-2728.2002.
- 411 COVID-19 developments in Indonesia.
- 412 Goh, G. K.-M., Dunker, A. K., Foster, J. A., and Uversky, V. N. (2020). Rigidity of the Outer Shell
413 Predicted by a Protein Intrinsic Disorder Model Sheds Light on the COVID-19 (Wuhan-2019-
414 nCoV) Infectivity. *Biomolecules* 10. doi:10.3390/biom10020331.
- 415 Griesemer, S. B., van Slyke, G., Ehrbar, D., Strle, K., Yildirim, T., Centurioni, D. A., et al. (2020).
416 Evaluation of specimen types and saliva stabilization solutions for SARS-CoV-2 testing.
417 *medRxiv*. doi:10.1101/2020.06.16.20133041.
- 418 Hung, K.-F., Sun, Y.-C., Chen, B.-H., Lo, J.-F., Cheng, C.-M., Chen, C.-Y., et al. (2020). New
419 COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat
420 swab test? *J. Chin. Med. Assoc.* 83, 891–894. doi:10.1097/JCMA.0000000000000396.
- 421 Iwasaki, S., Fujisawa, S., Nakakubo, S., Kamada, K., Yamashita, Y., Fukumoto, T., et al. (2020).
422 Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *J. Infect.* 81, e145–
423 e147. doi:10.1016/j.jinf.2020.05.071.
- 424 Landry, M. L., Criscuolo, J., and Peaper, D. R. (2020). Challenges in use of saliva for detection of
425 SARS CoV-2 RNA in symptomatic outpatients. *J. Clin. Virol.* 130.
426 doi:10.1016/j.jcv.2020.104567.
- 427 Lomas, J., Sunzeri, F., and Busch, M. (1992). False-negative results by polymerase chain reaction
428 due to contamination by glove powder. *Transfusion* 32, 83–85. doi:10.1046/j.1537-
429 2995.1992.32192116439.x.
- 430 Mak, G. C., Cheng, P. K., Lau, S. S., Wong, K. K., Lau, C. S., Lam, E. T., et al. (2020). Evaluation
431 of rapid antigen test for detection of SARS-CoV-2 virus. *J. Clin. Virol.* 129, 104500.
432 doi:10.1016/j.jcv.2020.104500.
- 433 Ott, I. M., Strine, M. S., Watkins, A. E., Boot, M., Kalinich, C. C., Harden, C. A., et al. Simply
434 saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices.
435 doi:10.1101/2020.08.03.20165233.
- 436 Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia (2020).
437 PANDUAN TATALAKSANA PEMERIKSAAN TES CEPAT MOLEKULER (TCM) dan
438 POLYMERASE CHAIN REACTION (PCR) SARS-CoV-2. *Website*. Available at:
439 https://www.pdspatklin.or.id/assets/files/pdspatklin_2020_04_30_19_20_35.pdf [Accessed May
440 25, 2021].
- 441 Scohy, A., Anantharajah, A., Bodéus, M., Kabamba-Mukadi, B., Verroken, A., and Rodriguez-
442 Villalobos, H. (2020). Low performance of rapid antigen detection test as frontline testing for
443 COVID-19 diagnosis. *J. Clin. Virol.* 129, 104455. doi:10.1016/j.jcv.2020.104455.
- 444 Smyrlaki, I., Ekman, M., Lentini, A., Rufino de Sousa, N., Papanicolaou, N., Vondracek, M., et al.
445 (2020). Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-
446 PCR. *Nat. Commun.* 11, 4812. doi:10.1038/s41467-020-18611-5.
- 447 Timeline of WHO’s response to COVID-19.
- 448 Viana, R. V, and Wallis, C. L. 3 Good Clinical Laboratory Practice (GCLP) for Molecular Based
449 Tests Used in Diagnostic Laboratories.
- 450 Vogels, C. B. F., Watkins, A. E., Harden, C. A., Brackney, D. E., Shafer, J., Wang, J., et al. (2020).

- 451 SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity.
452 *Med.* doi:10.1016/j.medj.2020.12.010.
- 453 Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., et al. (2020). Detection of SARS-CoV-2 in
454 Different Types of Clinical Specimens. *JAMA* 323, 1843–1844. doi:10.1001/jama.2020.3786.
- 455 Watkins, A. E., Fenichel, E. P., Weinberger, D. M., Vogels, C. B. F., Brackney, D. E., Casanovas-
456 Massana, A., et al. (2020). Pooling saliva to increase SARS-CoV-2 testing capacity. *medRxiv*.
457 doi:10.1101/2020.09.02.20183830.
- 458 WEATHER AND CLIMATE IN INDONESIA | Facts and Details.
- 459 Williams, E., Isles, N., Chong, B., Bond, K., Yoga, Y., Druce, J., et al. (2021). Detection of SARS-
460 CoV-2 in saliva: implications for specimen transport and storage. *J. Med. Microbiol.* 70.
461 doi:10.1099/jmm.0.001285.
- 462 World Health Organization (2020). Diagnostic testing for SARS-CoV-2. Available at:
463 <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>.
- 464 Wyllie, A. L., Fournier, J., Casanovas-Massana, A., Campbell, M., Tokuyama, M., Vijayakumar, P.,
465 et al. (2020). Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N.*
466 *Engl. J. Med.* 383, 1283–1286. doi:10.1056/nejmc2016359.
- 467 Xu, R., Cui, B., Duan, X., Zhang, P., Zhou, X., and Yuan, Q. (2020). Saliva: potential diagnostic
468 value and transmission of 2019-nCoV. *Int. J. Oral Sci.* 12, 11. doi:10.1038/s41368-020-0080-z.
- 469 Zhang, T., Cui, X., Zhao, X., Wang, J., Zheng, J., Zheng, G., et al. (2020). Detectable SARS-CoV-2
470 viral RNA in feces of three children during recovery period of COVID-19 pneumonia. *J. Med.*
471 *Viro.* 92, 909–914. doi:10.1002/jmv.25795.
- 472


473 **FIGURES AND LEGENDS**

474 **Fig 1A**



475

Fig 1B




476

477

478 **Figure 1. Optimization of RNA-Extraction-free treatment.** (A) Flowchart of eight different sample
 479 treatments prior SARS-CoV-2 detection (B) Bar graph represents means \pm SEM of three SARS-CoV-
 480 2 positive specimens tested for each sample treatment. Asterisk (*) denotes the treatments for
 481 comparison, where 1 is the comparative method while 6 is the candidate method.

482

483 **Fig 2**




484
485 **Figure 2. Linear regression of Ct values obtained from adding RNA extracted or heated-only**
486 **saliva for RT-qPCR template.** Data points in blue indicate Ct values for the detection of N-gene while
487 orange for the detection of ORF1ab. Results obtained from extracted RNA from saliva specimens were
488 plotted on the x-axis, while heated-only saliva on the y-axis. The line of best fit was plotted for both
489 target genes to display direct proportion between the two variables.

490

491

492 **Fig 3**


493



496

497 **Figure 3. Detection of SARS-CoV-2 target genes N-gene and ORF1ab remained stable for 5 days**
498 **at cold and room temperature storage conditions.** Relative Ct on the y-axis plots the difference
499 between Ct value obtained at a given day and Day 1 for the monitored sample. Data points in blue refer
500 to samples stored inside a refrigerator (2-8°C), while grey refer to samples stored at room temperature.
501 Straight lines display the average relative Ct obtained across storage days.

502 **Fig 4**



503

504 **Figure 4. Schematic workflow for collection and treatment of human saliva specimen for RNA-**
505 **extraction free detection of SARS-CoV-2 via RT-qPCR.**

506

507

508 **TABLES**

509 **Table 1. SARS-CoV-2 detection from RNA extracted from NPOP *versus* saliva sample types.**

Extracted saliva, n	NPOP		Total
	Positive	Negative	
Positive	60	0	60
Negative	11	32	43
Total	71	32	103
Agreements	%		95% CI
Overall*	89.32		81.88-93.93
Positive**	84.51		74.35-91.12
Negative***	100.00		89.28-100.00

*Overall agreement = ((60+32)/103) x 100

**Positive agreement = (60/71) x 100

***Negative agreement = (32/32) x 100

510
511
512
513

514 **Table 2. Validation of heated-only saliva as RNA-extraction free treatment**

Treated saliva, n	NPOP		Total
	Positive	Negative	
Positive	57	0	57
Negative	15	38	53
Total	72	38	110
Agreements	%		95% CI
Overall*	86.36		78.71-91.56
Positive**	79.17		68.43-86.95
Negative***	100.00		90.82-100.00

*Overall agreement = ((57+38)/110) x 100;

**Positive agreement = (57/72) x 100

***Negative agreement = (38/38) x 100

515
516
517

518

519

520 **Table 3. Performance of commercial kits using treated saliva as a template for RT-qPCR.** Rates
 521 of invalid and overall agreement were calculated as compared to results from the reference, Detection
 522 Kit for 2019 Novel Coronavirus (2019-nCoV) by Da An Gene Co.

523

Commercial kit	Sample size, n	Invalid specimens, n	Concordant to reference, n	Invalid rate, %	Overall agreement, %
Maccura	11	0	11	0.00	100.00
Fosun	12	1	11	8.33	100.00
Ardent	11	0	10	0.00	90.91
SD Biosensor	13	1	11	7.69	91.67
Biosewoom	11	1	8	9.09	80.00
Fortitude	11	1	7	9.09	70.00
3S	10	0	4	0.00	40.00
Vazyme	10	4	2	40.00	33.33

524
$$\text{Invalid rate (\%)} = \frac{\text{invalid specimens}}{\text{sample size}} \times 100$$

525
$$\text{Overall agreement (\%)} = \frac{\text{Concordant to reference}}{\text{Sample size} - \text{invalid specimens}} \times 100$$

526

527 **Table 4. Implementation of QuickSpit™ as collection and treatment method of saliva specimen**

Treated saliva collected with QuickSpit™, n	NPOP		Total
	Positive	Negative	
Positive	45	0	45
Negative	8	240	248
Total	53	240	293
Agreements	%		95% CI
Overall*	97.27		94.71-98.61
Positive**	84.91		72.95-92.15
Negative***	100.00		98.43-100.00

*Overall agreement = ((45+240)/293) x 100;

**Positive agreement = (45/53) x 100

***Negative agreement = (240/240) x 100

528
 529
 530
 531

532 **SUPPLEMENTARY INFORMATION**

533 **Supplementary 1. Optimization of RNA-Extraction-free treatment of saliva specimens.**

Treatment	Sample type	Extraction
1	NPOP	Qiagen
2	Saliva	Qiagen
3	Saliva	1. Transfer 100µl 2. Add 10ul Proteinase K 3. Incubate sample at 37°C for 30 mins 4. Heat inactivation at 95°C for 10 mins
4	Saliva	1. Transfer 100µl 2. Add 10ul Proteinase K 3. Incubate sample at 37°C for 15 mins 4. Heat inactivation at 95°C for 10 mins
5	Saliva	1. Transfer 100µl 2. Incubate sample at 37°C for 30 mins 3. Heat inactivation at 95°C for 10 mins
6	Saliva	1. Transfer 100µl 2. Heat inactivation at 95°C for 10 mins
7	Saliva	1. Transfer 100µl 2. Heat inactivation at 95°C for 10 mins 3. Centrifuge at max speed (13200 rpm) for 2 mins
8	Saliva	1. Transfer 100µl 2. Heat inactivation at 95°C for 10 mins 3. Centrifuge at max speed (13200 rpm) for 5 mins

534

535
536

Supplementary 2. Specifications and characteristics of the commercial RT-qPCR kits, as derived from their respective manufacturer's instructions

Kit name	Abbreviation*	Target Genes – Reporter Dye	Internal Control – Reporter Dye	LOD (copies/ml)	Reaction Volume (µl)	Template Volume (µl)	No. of Cycles	Cycle Cut-off
Detection Kit for 2019 Novel Coronavirus (2019-nCoV)	Da An Gene	N gene – FAM ORF1ab – VIC	RNase P – Cy5	500	25	5	45	40
Maccura SARS-CoV-2 Fluorescent PCR kit	Maccura	ORF1ab – FAM E gene – ROX N gene – Cy5	MS2 based pseudo virus – VIC/HEX	1000	20	20	40	38
Fosun COVID-19 RT-PCR Detection Kit	Fosun	ORF1ab – FAM E gene – ROX N gene – JOE	Lentivirus – Cy5	300	20	10	40	36
Novel Coronavirus (COVID-19) Nucleic Acid Detection Kit (PCR-fluorescent probe)	Ardent	ORF1ab (RdRp) – FAM N gene – VIC	RNase P – Cy5	400	15	5	45	40
Standard M nCoV Real-Time Detection kit	SD Biosensor	ORF1ab (RdRP) – FAM E gene-VIC/HEX	Internal control A (Pseudovirus) – Cy5	250	20	10	40	36
Real-Q 2019 nCoV Detection Kit	Biosewoom	RdRP gene – FAM E gene – HEX/VIC	HRP – Cy5	3125	20	5	40	38
*Based on kit name								

537

538 **Supplementary 2. Specifications and characteristics of the commercial RT-qPCR kits, as derived from their respective manufacturer's**
 539 **instructions (continue)**

Kit name	Abbreviation*	Target Genes – Reporter Dye	Internal Control – Reporter Dye	LOD (copies/ml)	Reaction Volume (µl)	Template Volume (µl)	No. of Cycles	Cycle Cut-off
MiRXES Fortitude kit 2.1	Fortitude	ORF1ab region 1 –FAM ORF1ab region 2 – HEX	Synthetic DNA oligo – Cy5	200	20	5	42	40
3S SARS-CoV-2 RT-PCR Kit	3S	N gene – FAM ORF1ab – HEX	β-actin – VIC/HEX	300	15	10	45	40
2019-Novel Coronavirus (2019-nCoV) Triplex RT-qPCR Detection Kit	Vazyme	ORF1ab – FAM N gene – ROX/Texas Red	RNase P – Cy5	200	30	20	45	38
* Based on kit name								


540

541 **Supplementary 3. SARS-CoV-2 detection from RNA extracted from NPOP *versus* saliva**
 542 **specimens.**

Extracted saliva, n	NPOP			Total
	Positive	Negative	Invalid	
Positive	60	0	2	62
Negative	11	32	2	45
Invalid	7	1	1	9
Total	78	33	5	116


543
544

545 **Supplementary 4. Comparison of eight different sample treatments prior to SAR-CoV-2**
 546 **detection via PCR for negative saliva specimens.** Bar graphs represent means \pm SEM for three
 547 SARS-CoV-2 negative specimens tested for each sample treatment illustrated in **Figure 1A**.



548
549

550 **Supplementary 5. Detection of SARS-CoV-2 target genes N and ORF1ab plotted as the Ct**
 551 **value obtained for monitored sample.** Data points collected in Day 1 are displayed as white circles
 552 with black outlines. Blue points refer to samples stored at cold while green at room temperature.
 553 Straight lines are drawn monitor changes for samples starting with the highest and lowest Ct value in
 554 Day 1.



555
556
557

558 **Supplementary 6. Validation as RNA-extraction-free treatment of saliva.**

Treated saliva, n	NPOP			Total
	Positive	Negative	Invalid	
Positive	57	0	1	58
Negative	15	38	3	56
Invalid	9	1	1	11
Total	81	39	5	125

559

560

561 **Supplementary 7. Performance of commercial kits using treated saliva as template for RT-**
 562 **qPCR.**

Commercial kit	Sample size, n	True positive, n	False positive, n	True negative, n	False negative, n	Invalid samples, n	Invalid rate, %	Overall agreement, %	Estimated sensitivity, %
Maccura	11	11	0	0	0	0	0.00	100.00	100.00
Fosun	12	6	0	5	0	1	8.33	100.00	100.00
Ardent	11	10	0	0	1	0	0.00	90.91	90.91
SD Biosensor	13	8	0	3	1	1	7.69	91.67	88.89
Biosewoom	11	8	0	0	2	1	9.09	80.00	80.00
Fortitude	11	7	0	0	3	1	9.09	70.00	70.00
3S	10	2	6	2	0	0	0.00	40.00	100.00
Vazyme	10	2	4	0	0	4	40.00	33.33	100.00

563

564

565 **Supplementary 8. Implementation of QuickSpit™ as a device for collection of saliva specimen.**

Treated saliva collected with QuickSpit™, n	NPOP			Total
	Positive	Negative	Invalid	
Positive	45	0	0	45
Negative	8	240	2	250
Invalid	10	1	0	11
Total	63	241	2	306

566

567

568 **Supplementary 9. Calculation of invalid samples in the different specimens and treatment conditions.**

	Extracted NPOP	Extracted saliva	Treated saliva	Treated saliva collected with QuickSpit™
valid	535	107	114	295
invalid	29	9	11	11
total, n	564	116	125	306
% invalid	5.14	7.76	8.80	3.59

569